


Base & Prime Editing Move from Hype to Timelines: What Hits Patients 2026–2030?
Beyond CRISPR Hype Gene editing has promised to revolutionize medicine,

Gene Editing for Everyone: CRISPRware and the Open-Source Biotech Revolution
CRISPRware Signals a New Era in Democratized Gene Editing In

Cholesterol Rewritten: Verve’s Base Editing Therapy May Disrupt a $20B Market
High cholesterol has long been a silent threat lurking in

CRISPR-Cas9 Enhances Rice Yields Without Introducing Foreign DNA
This study explores the use of CRISPR-Cas9 technology to increase

Innovative Breakthrough in Genomics: Profluent’s OpenCRISPR-1 Revolutionizes Human Genome Editing
In a groundbreaking achievement, the biotechnology firm Profluent has successfully
